Real-world use of the Moderna and Pfizer vaccines in the United States reveals that both are working at 90% efficacy - with data pointing to one dose being capable of 80% protection.
Tore K Kvien & Guro L Goll argue that biosimilars are an opportunity for improving access to treatment & reducing cost and provide comment on the NOR-SWITCH study.
EU leaders today (25 March) decided not to create an export ban for AstraZeneca vaccines made for the UK - but the feud between AstraZeneca and the bloc remains close to the surface of future discussions.
In a study of over 32,000 people, a US trial found the AstraZeneca vaccine was 100% effective against deaths caused by COVID-19 - the vaccine did not show any connection to blood clots.
Professor Heather Sheardown, C20/20 Ophthalmic Materials Innovation Hub, Department of Chemical Engineering, McMaster University, explores how polymers can be used to treat dry eye disease.
The safety committee of the European Medicines Agency said the investigation did not prove that AstraZeneca vaccinations cause blood clots - describing the possibility as an "extremely small likelihood".
Currently, several EU countries are suspending use of the AstraZeneca vaccine due to reports of blood clot risks - in response, people are speaking out about the higher risk of blood clots posed by contraceptive pills used globally.
Over the weekend, the Republic of Ireland suspended their use of AstraZeneca due to reports of blood clots in Norway - in response, the European Medicines Agency (EMA) says the AstraZeneca vaccine is still safe to use.
The US based vaccine appears to be 96.4% effective against the original COVID mutation, with 86% efficacy against the UK variant and only 55% against the South African variant.
Israel faced international criticism on their refusal to vaccine Palestinians - now, the country will begin rolling out Pfizer shots to some Palestinians who have work permits.
